# US 2008/0306083 A1 · Biaryl Compounds Useful as Agonists of the Gpr38 Receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306083 A1
- Document ID: US20080306083A1
- Status: Published application
- Kind: A1
- Application number: 12/096,104
- Filed: 2006-12-01
- Published: 2008-12-11
- Earliest claimed: 2005-12-05
- Assignees: Glaxo Group Limited
- Inventors: Gregor James MacDonald; Darren Jason Mitchell; Mervyn Thompson; Susan Marie Westaway
- Web page: https://patentgrep.com/patent/US20080306083A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel biaryl derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof,
wherein
A is selected from a 5 or 6 membered heteroaryl ring and an N-linked 5 or 6 membered heterocyclic ring; which ring is optionally substituted with 1, 2 or 3 groups independently selected from halogen, C(1-4) alkyl and C(1-4) alkoxy;
R1 and R2 are independently selected from H or C(1-4) alkyl;
Y is selected from NH, O and CH2;
R3 is selected from optionally substituted phenyl and optionally substituted 5 or 6 membered heteroaryl;
and when R3 is substituted, it may have 1, 2 or 3 substituents, each independently selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, C(3-7)cycloalkyl, hydroxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, phenyl, NH2, NHR4, NR4R5, NHCOR4, NHSO2R4, C(O)CF3, C(O)C(1-4)alkyl, C(O)C(3-7)cycloalkyl, C(O)OC(1-4)alkyl, C(O)OC(3-7)cycloalkyl, OC(O)C(1-4)alkyl, OC(O)C(3-7)cycloalkyl, CONH2, CONHR4, CONR4R5, SOR5, SO2R5, OSO2R5, OSO2CF3, SO2NH2, SO2NHR4 and SO2NR4R5;
where R4 and R5 may be the same or different and are independently selected from C(1-4) alkyl, phenyl optionally substituted with halogen, and 5 or 6 membered heteroaryl optionally substituted with halogen.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 in which A is a 5 or 6 membered heteroaryl ring, optionally substituted with 1, 2 or 3 groups independently selected from halogen, C(1-4) alkyl and C(1-4) alkoxy;

### Claim 3 (depends on 1)

A compound as claimed in claim 1 in which A is selected from pyrazolyl, thiazolyl, furanyl, thienyl and pyridyl.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 in which R3 is optionally substituted phenyl.

### Claim 5 (depends on 1)

A compound as claimed in claim 1 in which R3 is substituted by 1, 2 or 3 groups selected from halogen, cyano, C(1-4)alkyl, C(1-4)alkoxy, C(3-7)cycloalkyl, trifluoromethoxy and trifluoromethyl.

### Claim 6 (depends on 1)

A compound as claimed in claim 1 in which Y is NH.

### Claim 7 (depends on 1)

A compound as claimed in claim 1 selected from:
1-[3-(3-{[(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl}-1H-pyrazol-yl)-2-pyridinyl]-N-(4-fluorophenyl)-4-piperidinamine (E1)
1-[3-(3-{[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl}-1H-pyrazol-1-yl)-2-pyridinyl]-N-(3-fluorophenyl)-4-piperidinamine (E2)
1-[3-(3-{[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl}1H-pyrazol-1-yl)-2-pyridinyl]-N-(2-fluorophenyl)-4-piperidinamine (E3)
1-[3-(5-{[(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl}-1,3-thiazol-2-yl)-2-pyridinyl]-N-(4-fluorophenyl)-4-piperidinamine (E4)
1-[3-(5-{[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl}2-furanyl)-2-pyridinyl]-N-(4-fluorophenyl)-4-piperidinamine (E5)
1-[3-(5-{[(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl}-2-thienyl)-2-pyridinyl]-N-(4-fluorophenyl)-4-piperidinamine (E6)
1-[3-(4-{[(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl}-1,3-thiazol-2-yl)-2-pyridinyl]-N-(4-fluorophenyl)-4-piperidinamine dihydrochloride (E7)
1-[3-(4-{[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl}-1,3-thiazol-2-yl)-2-pyridinyl]-N-(3-fluorophenyl)-4-piperidinamine (E8)
1-[3-(4-{[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl}-1,3-thiazol-2-yl)-2-pyridinyl]-N-(2-fluorophenyl)-4-piperidinamine (E9)
1-(5-{[(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl}2,3′-bipyridin-2′-yl)-N-(4-fluorophenyl)-4-piperidinamine (E10)
N-(4-Fluorophenyl)-1-[3-(3-{[(3S)-3-methyl-1-piperazinyl]methyl}1H-pyrazol-1-yl)-2-pyridinyl]-4-piperidinamine (E11)
(3R,5S)-1-{[1-(2-{4-[(4-Fluorophenyl)oxy]-1-piperidinyl}-3-pyridinyl)-1H-pyrazol-3-yl]methyl}3,5-dimethylpiperazine (E12)
(3R,5S)-1-{[1-(2-{4-[(2-Fluorophenyl)oxy]-1-piperidinyl}-3-pyridinyl)-1H-pyrazol-3-yl]methyl}-3,5-dimethylpiperazine (E13)
(3R,5S)-1-{[1-(2-{4-[(3-Fluorophenyl)oxy]-1-piperidinyl}-3-pyridinyl)-1H-pyrazol-3-yl]methyl}-3,5-dimethylpiperazine (E14)
(3S)-1-{[1-(2-{4-[(3-Fluorophenyl)oxy]-1-piperidinyl}-3-pyridinyl)-1H-pyrazol-3-yl]methyl}-3-methylpiperazine (E15)
(3S)-1-{[1-(2-{4-[4-Fluorophenyl)oxy]-1-piperidinyl}-3-pyridinyl)-1H-pyrazol-3-yl]methyl}3-methylpiperazine monohydrochloride (E16)
1-(5-{[(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl}-2,3′-bipyridin-2′-yl)-N-(3-fluorophenyl)-4-piperidinamine (E17)
N-(4-Fluorophenyl)-1-(5-{[(3S)-3-methyl-1-piperazinyl]methyl}-2,3′-bipyridin-2′-yl)-4-piperidinamine (E18)
N-(4-Fluorophenyl)-1-[5-(1-piperazinylmethyl)-2,3′-bipyridin-2′-yl]-4-piperidinamine hydrochloride (E19)

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 9

9-12. (canceled)

### Claim 13

A method of treatment of a condition or disorder in a mammal which can be mediated via the GPR38 receptor, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A process for the preparation of a compound as claimed in claim 1 or a pharmaceutically acceptable salt or solvate thereof, which process comprises reacting a compound of formula (II),
wherein A, Y and R3 are as defined in claim 1, with an appropriately substituted piperazine (III),
wherein R1 and R2 are as defined in claim 1 and Q is hydrogen or a suitable nitrogen protecting group, in reaction conditions suitable for a reductive alkylation, in a suitable solvent,
and thereafter optionally carrying out one or more of the following reactions:
1. Converting one compound of formula (I) into another compound of formula (I);
2. Removing any protecting group;
3. Forming a suitable pharmaceutical acceptable salt or solvate of the compound so formed.

### Claim 15 (depends on 1)

A process for the preparation of a compound as claimed in claim 1 wherein A is pyrazolyl, or a pharmaceutically acceptable salt or solvate thereof, which process comprises reacting a compound of formula (VIII),
wherein R1 and R2 are as defined in claim 1 and Q is hydrogen or a suitable nitrogen protecting group, with a compound of formula (IV),
wherein Y and R3 are as defined in claim 1 and L is a leaving group, in the presence of a suitable base, in the presence of a suitable catalyst in a suitable solvent;
and thereafter optionally carrying out one or more of the following reactions:
1. Converting one compound of formula (I) into another compound of formula (I);
2. Removing any protecting group;
3. Forming a suitable pharmaceutical acceptable salt or solvate of the compound so formed.

### Claim 16 (depends on 1)

A process for the preparation of a compound as claimed in claim 1 or a pharmaceutically acceptable salt or solvate thereof, which process comprises reacting a compound of formula (XI),
wherein A, R1 and R2 are as defined in claim 1, L is a leaving group and Q is hydrogen or a suitable nitrogen protecting group, with a compound of formula (XII),
wherein Y and R3 are as defined in claim 1, in the presence of a suitable base, in the presence of suitable catalyst, in a suitable solvent;
and thereafter optionally carrying out one or more of the following reactions:
1. Converting one compound of formula (I) into another compound of formula (I);
2. Removing any protecting group;
3. Forming a suitable pharmaceutical acceptable salt or solvate of the compound so formed.

### Claim 17 (depends on 1)

A process for the preparation of a compound as claimed in claim 1 or a pharmaceutically acceptable salt or solvate thereof, which process comprises reacting a compound of formula (XIII),
wherein A, R1 and R2 are as defined in claim 1 and Q is hydrogen or a suitable nitrogen protecting group, with a suitable aniline, under reaction conditions suitable for a reductive alkylation, in the presence of an acid, in the presence of molecular sieves and in a suitable solvent;
and thereafter optionally carrying out one or more of the following reactions:
1. Converting one compound of formula (I) into another compound of formula (I);
2. Removing any protecting group;
3. Forming a suitable pharmaceutical acceptable salt or solvate of the compound so formed.
